An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the routine clinical use and the safety and efficacy
of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible
participants will be followed for up to 24 months.